GRI Bio, Inc.
GRI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001824293
No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding GRI Bio, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 11 | 12 | +1 |
| Shares | 579.3K | 378.5K | −200.8K (−34.7%) |
| Value | $3.15M | $2.75M | −$399.0K (−12.7%) |
New holders (3)
Institutions that held GRI Bio, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| State Street Corp | 11,200 | $81.0K | 0.00% |
| Morgan Stanley | 2,628 | $19.0K | 0.00% |
| Total Clarity Wealth Management, Inc. | 1,000 | $7.00K | 0.00% |
Sold out (2)
Institutions that held GRI Bio, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Altium Capital Management LP | 161,440 | $878.0K |
| Tower Research Capital LLC (TRC) | 17 | $0 |